Highlights

  • BLS Pharmaceuticals (ASX:BLS) recorded Q1 FY27 revenue of A$26.7 million, a quarterly record and 23% above Q4 FY26.
  • FY26 revenue reached A$74.2 million, with adjusted EBITDA of A$19.0 million and NPAT of A$15.4 million.
  • FY27 guidance of A$105 million to A$115 million revenue and a 23% to 26% adjusted EBITDA margin was reaffirmed.
  • Cash stood at A$12.7 million at 30 September 2026, with net operating cash flow of A$2.0 million for the quarter.

BLS Pharmaceuticals Limited is an Australian company that manufactures, develops and commercialises regulated therapeutic products and active pharmaceutical ingredients, operating mainly through its wholly owned subsidiary, Breathe Life Sciences. The company released its first-quarter FY27 report in mid-October 2026, following full-year results in late August and a change of name and ASX code earlier in the year.

Company Business

Breathe Life Sciences holds GMP manufacturing, import, export, wholesale and distribution licences for controlled substances, including medicinal cannabis, psilocybin and MDMA. Its main manufacturing hub is a Brisbane GMP facility, which the company estimates has annual revenue capacity of more than A$250 million.

BLS Pharmaceuticals (ASX:BLS) has operations and customers in Australia, Europe, the United Kingdom and Japan, and made its first commercial supply into Costa Rica during FY26, marking entry into Latin America. A second GMP facility is under development in the Scottish Borders and is awaiting regulatory approval, with the chief executive describing the site as complete and ready for inspection and licensing.

Recent Development

The company changed its name from Bioxyne Limited to BLS Pharmaceuticals Limited, with the new ASX code beginning trading on 7 July 2026. In July 2026 it signed a referral agreement with Cayman Chemical, through subsidiary BLS Wholesalers, covering psilocybin and MDMA dosage forms, and a non-binding Heads of Agreement with Trexapharm to become the preferred Australian commercial partner for TREXAVIVE.

BLS Pharmaceuticals (ASX:BLS) was added to the S&P/ASX All Ordinaries Index effective 21 September 2026. In its quarterly report for the period ended 30 September 2026, the company said it supplies ADREXpharma in Germany under a two-year contract valued at about A$50 million, which includes a minimum purchase commitment of A$25 million in the first 12 months. It also began manufacturing for Aurora Cannabis during FY26. An A$3.0 million Westpac overdraft facility executed in July 2026 remains undrawn.

Financial Performance and Sector Context

For the year ended 30 June 2026, revenue was A$74.2 million, compared with A$28.4 million in the prior year, an increase of 161%. Adjusted EBITDA was A$19.0 million, up 171% and equal to a margin of about 26%. Net profit after tax was A$15.4 million, compared with A$4.9 million, and net operating cash flow was A$5.4 million. Cash at 30 June 2026 was A$13.3 million.

In the September 2026 quarter, revenue rose to A$26.7 million from A$21.7 million in the June quarter. Net operating cash flow was A$2.0 million, compared with A$6.3 million in the previous quarter. Investing outflows were A$2.7 million, including A$2.4 million for the Scotland facility. Cash at 30 September 2026 was A$12.7 million.

The company reaffirmed FY27 guidance for revenue of A$105 million to A$115 million, implying growth of 42% to 55% on FY26, and an adjusted EBITDA margin of 23% to 26%. Adjusted EBITDA is a non-IFRS measure that also excludes share-based payments.

Sector conditions are shaped by regulation of controlled substances, with licensing, import and export permits and GMP standards affecting how products are made and shipped.

Risks to Consider

Delivery of guidance depends on higher manufacturing utilisation at Brisbane, onboarding new customers and executing international supply agreements. The Scotland facility remains subject to regulatory approval, and licensing timelines can change. The non-binding Trexapharm agreement is not a binding commitment. BLS Pharmaceuticals (ASX:BLS) also depends on delivery of supply contracts such as the ADREXpharma agreement and faces currency exposure, licensing requirements and changes in drug regulation across Australia, Europe, the United Kingdom and Japan. Operating cash flow fell between the June and September quarters while capital spending on Scotland continued.

What to Watch Next

Priorities set out for the second quarter of FY27 include increasing manufacturing utilisation, onboarding customers, executing international supply agreements and progressing the Scotland facility toward approval. Progress on the Trexapharm agreement and the Cayman Chemical referral arrangement is also worth following. No dates for the next quarterly report or the annual general meeting were stated in the latest report.

Key Insights

BLS Pharmaceuticals (ASX:BLS) enters FY27 with record quarterly revenue, reaffirmed guidance and a second manufacturing site awaiting licensing. Reported cash of A$12.7 million and modest drawn debt frame the funding position as capital continues to be spent in Scotland. Monitoring points include quarterly revenue against the A$105 million to A$115 million guidance range, Scotland approval and contract execution.